Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNMFree Report) in a report issued on Friday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, Maxim Group cut their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.40.

Get Our Latest Stock Analysis on ATNM

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock traded down $0.15 during trading on Friday, reaching $1.50. The company’s stock had a trading volume of 631,169 shares, compared to its average volume of 446,255. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24. The company has a 50-day moving average price of $1.79. The stock has a market capitalization of $46.79 million, a P/E ratio of -0.99 and a beta of 0.14.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Los Angeles Capital Management LLC acquired a new position in Actinium Pharmaceuticals in the 3rd quarter worth approximately $322,000. XTX Topco Ltd purchased a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $268,000. Marshall Wace LLP increased its stake in shares of Actinium Pharmaceuticals by 67.9% in the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares during the period. Vanguard Group Inc. raised its holdings in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the last quarter. Finally, Virtu Financial LLC lifted its position in Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

Recommended Stories

Analyst Recommendations for Actinium Pharmaceuticals (NYSE:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.